Frean John, Klugman Keith P, Arntzen Lorraine, Bukofzer Stanley
National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.
J Antimicrob Chemother. 2003 Aug;52(2):297-9. doi: 10.1093/jac/dkg364. Epub 2003 Jul 15.
To determine the susceptibility of southern African strains of Bacillus anthracis to new, investigational agents as well as conventional antibiotics.
The MICs of 26 isolates of B. anthracis from South Africa and Zimbabwe, as well as the Sterne vaccine strain and a type culture strain, were determined by agar dilution.
The most active antimicrobial agents were the novel ketolide ABT 773, new and conventional fluoroquinolones, and doxycycline; macrolides were intermediately active. The lack of activity of extended-spectrum cephalosporins against B. anthracis was confirmed.
Susceptibility to conventional antibiotics was in keeping with previous studies. Two new fluoroquinolones and a ketolide showed promising in vitro activity that would support their further evaluation in animal models of anthrax.
确定南部非洲炭疽芽孢杆菌菌株对新型研究性药物以及传统抗生素的敏感性。
采用琼脂稀释法测定了来自南非和津巴布韦的26株炭疽芽孢杆菌分离株、斯特恩疫苗株和一个模式培养菌株的最低抑菌浓度（MIC）。
活性最强的抗菌药物是新型酮内酯ABT 773、新型和传统氟喹诺酮类药物以及强力霉素；大环内酯类药物活性中等。证实了广谱头孢菌素对炭疽芽孢杆菌无活性。
对传统抗生素的敏感性与先前研究一致。两种新型氟喹诺酮类药物和一种酮内酯在体外显示出有前景的活性，这将支持它们在炭疽动物模型中进行进一步评估。
